<p>Guillermo Garcia-Manero discusses a phase 1/2 study on sequential azacitidine and lenalidomide in high-risk MDS and AML.</p>

Guillermo Garcia-Manero discusses a phase 1/2 study on sequential azacitidine and lenalidomide in high-risk MDS and AML.

The Lancet Haematology: January 7, 2015

Lan-Lan Smith, Editor-in-Chief of The Lancet Haematology, and the journal’s authors explore their research and its impact on people’s health, health care, and health policy in this regular podcast.

Share The Lancet Haematology: January 7, 2015

Sign up to save your podcasts

The Lancet Haematology: January 7, 2015

The Lancet Haematology: January 7, 2015